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Calcium-sensing receptor and calcimimetic agents. Recogniz- inverse relationship between parathyroid hormone (PTH)
ing the role of the extracellular calcium-sensing receptor (CaR) levels and small changes of blood Ca21 [1] and the sharp
in mineral metabolism greatly improves our understanding of rise in urinary Ca that occurs as serum Ca rises slightlycalcium homeostasis. The biology of the low affinity, G-protein-
above a “threshold” value. This provides the mechanismcoupled CaR and the effects of its activation in various tissues
whereby the body controls calcium homeostasis andare reviewed. Physiological roles include regulation of parathy-
roid hormone (PTH) secretion by small changes in ionized tightly regulates the blood Ca21. Alterations of this re-
calcium (Ca21) and control of urinary calcium excretion with ceptor are responsible for certain disease states, includ-
small changes in blood Ca21. The CaR also affects the renal
ing familial hypocalciuric hypercalcemia (FHH) [3], se-handling of sodium, magnesium and water. Mutations affecting
vere infantile hyperparathyroidism [4, 5], and hereditarythe CaR that make it either less or more sensitive to Ca21
cause various clinical disorders; heterozygotes of mutations forms of hypoparathyroidism [6, 7]. Acquired alterations
causing the CaR to be less sensitive to extracellular Ca21 cause in the expression of CaR may play a role in the pathogen-
familial hypocalciuric hypercalcemia, while the homozygous esis of secondary and primary hyperparathyroidism. Aform results in severe infantile hyperparathyroidism. Mutations
“calcimimetic” compound that enhances the affinity ofcausing increased sensitivity of the CaR to extracellular Ca21
the CaR for Ca21 and reduces PTH secretion [8] has beenproduce hereditary forms of hypoparathyroidism. Disorders,
such as primary and secondary hyperparathyroidism, may ex- explored as potential therapy for primary and secondary
hibit acquired abnormalities of the CaR. Calcimimetic drugs, hyperparathyroidism. This review describes the CaR, its
which amplify the sensitivity of the CaR to Ca21, can suppress
characteristics and its presumed roles in various physio-PTH levels, leading to a fall in blood Ca21. Experiences with
logic and pathophysiologic states. Several clinical disor-this agent in patients with secondary and primary hyperpara-
thyroidism and parathyroid carcinoma are summarized. In ani- ders involving the CaR are reviewed, and early data on
mals and humans with hyperparathyroidism, this agent pro- the clinical use of a calcimimetic agent are presented.
duces a dose-dependant fall in PTH and blood Ca21, with larger
doses causing more sustained effects. The treatment has been
short-term except for one patient followed for more than 600 CHARACTERISTICS OF THE
days for parathyroid carcinoma; nonetheless the drug did not CALCIUM RECEPTORcause major side-effects and appears to be safe. Further long-
term controlled studies are needed with calcimimetic agents The features of the CaR, a member of the superfamily
of this type. of G-protein-coupled receptors, are reviewed in detail
elsewhere [9–11]. It has a large extracellular domain
comprised of approximately 700 amino acids, seven
The discovery and cloning of the extracellular calcium- membrane-spanning segments, and a cytoplasmic car-
sensing receptor (CaR) and its molecular role in mineral boxyl terminal segment consisting of approximately 200
metabolism represent a major scientific advance during amino acids. Unique in comparison to many hormone
the last decade [1, 2]. This low affinity, G-protein-coupled receptors, which are activated by nanomolar quantities
receptor is found in high concentrations on the surface of agonist, the CaR is sensitive to relatively small changes
of parathyroid cells, on calcitonin-secreting C-cells of in Ca21 in extracellular fluid having a very high concen-
the thyroid, at various sites along the nephron, in certain tration of extracellular Ca21 (over 1 mm). The CaR is a
areas of the brain, on bone cells, and in other tissues. G-protein coupled receptor that on activation stimulates
The activation of this receptor by small changes in extra- phospholipase C (PLC), which results in increased levels
cellular ionized Ca (Ca21) accounts for both the steep of inositol 1,3,5-triphosphate (IP3), which in turn ele-
vates the cytosolic Ca21 activity by mobilizing Ca from
various intracellular sites. Activation of the CaR alsoKey words: blood ionized calcium, parathyroid carcinoma, primary
hyperparathyroidism, secondary hyperparathyroidism. inhibits the accumulation of hormone-stimulated intra-
cellular cAMP [1]. 1999 by the International Society of Nephrology
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Table 1. Potential clinical and physiologic implications of the extracellular calcium-sensing receptor (CaR)
• PTH Control by ECF Ca21: Steep relationship between PTH secretion and ECF.
• Ca21; may account for the “set point” for PTH release. CaR also controls PTH synthesis.
• Renal Ca excretion: Steep relationship between ECF Ca21 and urinary Ca excretion as serum Ca21 rises slightly.
• Pathophysiology of familial hypocalciuric hypercalcemia (FHH): Heterozygotic genetic mutations have CaR that are less sensitive to ECF Ca21.
Homozygotic forms of the same mutation(s) present with neonatal severe hyperparathyroidism (NSHPT).
• Pathophysiology of autosomal dominant hypoparathyroidism (ADHP): This condition arises from mutations in the CaR gene making the CaR
more sensitive to ECF Ca21.
• Symptoms and features of hypercalcemia/hypercalciuria: May explain the polyuria, diminished urinary concentrating ability, thirst, hypermagnesi-
uria with tendency to hypomagnesemia and natriuresis (particularly during calcium infusion).
• Regulation of calcitriol synthesis: CaR may underlie the control of renal synthesis of calcitriol by changes in ECF Ca21 that occur independent
of PTH.
• Effects of hypermagnesemia: PTH suppression and development of hypercalciuria and natriuresis.
• Manifestations of aminoglycoside toxicity: CaR may explain the polyuric acute renal failure, hypomagnesemia and even a mechanism for the
renal tubular uptake of aminoglycosides.
• Calcimimetic agents: Potential therapeutic compounds for treatment of primary and secondary hyperparathyroidism.
Abbreviations: ECF, extracellular fluid; Ca21, ionic calcium concentration.
Another feature of the CaR is its lack of specificity; tion in the CTAL may account for the effects of increased
extracellular concentrations of Ca21 and Mg21 to inhibitthus, it is stimulated by other divalent cations, such as
magnesium, by the trivalent elements, gadolinium and the reabsorption of calcium, magnesium, sodium and
chloride at this tubular site. Normally, Ca and Mg reab-lanthanum, and by polycationic compounds, such as neo-
mycin and spermine. It is likely that the affinity of magne- sorption occurs through the intercellular space and is
driven by the high transtubular voltage gradient that issium for the CaR is responsible for the effects of hyper-
magnesemia to suppress PTH secretion [12]. Also, many generated by the luminal Na1K12Cl2 transporter. Acti-
vation of the apical CaR stimulates PLC which releaseseffects of elevated serum magnesium levels on the renal
handling of calcium, sodium and chloride [13, 14] proba- arachidonic acid that is, in turn, metabolized by cyto-
chrome P450; the active metabolites inhibit the apicalbly arise because of the activation of the renal tubular
CaR by Mg21. The activation of the CaR by the polyva- K1 channel and may also directly inhibit the Na1K12Cl2
cotransporter. These effects result in a marked reductionlent cations, neomycin and gentamicin, may account for
certain effects of these agents on the kidney, including in transluminal voltage, leading to reduced paracellular
transport of Ca and Mg. Activation of the CaR alsothe development of nonoliguric renal failure, perhaps
due to impairment of the vasopressin-sensitive renal con- inhibits the PTH stimulated adenylate cyclase, reducing
the cAMP-mediated transport of Ca and Mg.centrating mechanism via activation of the CaR of the
collecting duct. Certain physiological roles and clinical In the IMCD, increased Ca21 inhibits the generation
of cAMP by vasopressin through the effect of Ca21 onimplications of the CaR are listed in Table 1.
the CaR at the basolateral surface, a factor leading to
Role of CaR in parathyroid cells less concentrated urine and polyuria. Also, increased
tubular fluid Ca21 activates the luminal CaR which spe-The secretory response of the parathyroid cell to
changes in blood Ca21 occurs within seconds, an observa- cifically reduces ADH-stimulated osmotic H2O perme-
ability via the aquaporin channels and lowers the urinarytion suggesting that Ca21 acts directly on the plasma
membrane [1]. The presence of CaR in very high concen- concentrating ability [17]. The action of increased ECF
Ca21 to inhibit the Na1K12Cl2 cotransporter located intrations on the parathyroid cell membrane provides the
extracellular Ca21-sensing mechanism for these cells. the thick ascending limb reduces the medullary hyperto-
nicity and therefore the effectiveness of the countercur-The extracellular domain of the CaR contains several
clusters of acidic amino acids that are involved in Ca21 rent mechanism and reduces further the maximum uri-
nary concentrating ability.binding. This provides a mechanism whereby the CaR
regulates the secretion of PTH in response to small Thus, the effect of hypercalcemia to lower GFR, to
reduce the renal cortical synthesis of calcitriol [18], tochanges in extracellular Ca21 concentration [11, 15].
cause increased urinary excretion of both Ca and Mg,
Role of CaR in the kidney and to lead to increased volumes of dilute urine may
arise, in whole or in part, through activation of the CaRWithin the kidney, transcripts of the CaR have been
found in the juxtaglomerular apparatus, along the lumi- within various parts of the nephron.
nal proximal convoluted tubule, the basolateral surface
CaR in other tissuesof the cortical thick ascending limb (CTAL), and the
apical as well as luminal membrane of the inner medul- The roles of the CaR that are found in the intestine
[19], parts of the brain [20], and the lungs remain to belary collecting duct (IMCD) [10, 16]. The CaR localiza-
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clarified. It is probable that Ca21 activation of a Ca21- those produced by the treatment, early recognition of
such cases is important for proper management.sensitive receptor acts to stimulate bone formation and to
There may be acquired disorders involving the CaR.inhibit bone resorption; moreover, the G-protein-coupled
Various data indicate that parathyroid glands obtainedCaR has been identified in bone cell precursors [21].
surgically from uremic patients with secondary hyper-Alternatively, Ca21-sensing proteins of other types may
parathyroidism may exhibit reduced expression of theplay a role in regulating bone metabolism [22, 23].
CaR on the surface of parathyroid cells [31, 32]. In pa-It seems apparent that the very tight regulation of
tients with parathyroid adenomas or parathyroid carci-blood Ca21, which is affected in a major way by PTH,
noma the data are somewhat inconsistent, although re-calcitriol, and, to a lesser extent, by calcitonin, occurs
duced staining is found in some glands. It is possible thatdue to the tight “fine tuning” that arises from activation
changes in the density of CaR in parathyroid cells mayof the CaR to modulate PTH secretion and to regulate
account, in part, for the shift in “set point” of parathyroidthe renal excretion of calcium.
cells (i.e., the calcium concentration required to suppress
maximal PTH secretion by 50%). In experimental ani-
CLINICAL DISORDERS INVOLVING THE CaR mals, data suggesting that there is regulation of the CaR
are either negative or controversial. Two studies doneSeveral inherited disorders and acquired conditions
in vitamin D-deficiency rats have demonstrated no regu-involving calcium metabolism may arise from aberra-
lation of the mRNA for CaR by Ca21 [33, 34]. One studytions in the structure or density of the CaR. The patho-
reported no effect of calcitriol on the mRNA for thegenesis of the peculiar syndrome, benign familial hypo-
CaR, while another study found a 40% reduction ofcalciuric hypercalcemia (FHH) may be explained by one
mRNA for CaR in vitamin D-deficient rats that wasor more mutations causing a partial loss of sensitivity of
restored by calcitriol replacement [34]. Thus, some un-the CaR to Ca21 [3, 4, 24]. This genetic defect is associ-
certainty exists about the role of altered regulation ofated with enhanced renal tubular reabsorption of cal-
the CaR being a major factor predisposing to the devel-cium leading to a rise in serum Ca with a consequent
opment of progressive secondary hyperparathyroidismincrease in the filtered load of Ca. The rise in serum Ca
in patients with progressive renal failure.is not sufficient to suppress PTH secretion because of
Experimental data indicate there are increases in thethe reduced affinity of Ca21 for the CaR on parathyroid
density of the CaR on the parathyroid cells of rats ofcells. These patients are totally asymptomatic, but they
increasing age but with decreased response; in the kid-have persistent mild hypercalcemia, low urinary Ca, and
ney, no alterations in the CaR were observed [35]. If aserum PTH levels that are not suppressed appropriately
similar process exists in man, it could account for thebut are in the upper range of normal or even above
changes in PTH levels with age and the propensity fornormal. Of interest, these patients exhibit a normal uri-
the development of hyperparathyroidism with advancingnary concentrating capacity, in contrast to findings in
years. There is evidence that the CaR expression in renalpatients with primary hyperparathyroidism [25]. The
tissue is modestly reduced in experimentally inducedcondition, neonatal severe hyperparathyroidism, with se-
renal failure in rats; this might contribute to hypo-vere hypercalcemia and multiple fractures that arise due
calciuria noted with renal insufficiency [36].to hyperparathyroid bone disease, represents the homo-
zygotic inheritance of this mutation [19, 26]. In knockout
mice lacking the CaR, modest and benign elevations of EXPERIMENTAL AND CLINICAL USE OF
CALCIMIMETIC AGENTSserum Ca and hypocalciuria are observed in heterozy-
gotes, while homozygotes exhibit severe hypercalcemia, For the clinician, the development calcimimetic com-
markedly elevated PTH levels, skeletal abnormalities pounds that modulate the CaR making it more sensitive
and premature death [27]. Mutations of other types that to Ca21 and that can suppress PTH secretion may provide
involve the CaR have been reported to cause somewhat a means for the medical treatment for both primary and
less severe forms of neonatal hyperparathyroidism [3, secondary hyperparathyroidism. The compound, R-568,
28]; these are beyond the scope of this review. which was developed by scientists at NPS Pharmaceuti-
The syndrome of autosomal dominant hypocalcemia cals [37, 38], has undergone the most extensive testing.
with hypercalciuria is now known to arise from several In rats with experimental uremia, the proliferation of
mutations that result in increased sensitivity of the CaR parathyroid cells, which is increased in this model of
to Ca21 [6, 7, 29]. The affected individuals generally have secondary hyperparathyroidism, was measured by in vivo
severe hypocalcemia that is often treated with calcium labelling with 5-bromodeoxyuridine (BrdU). Groups of
and vitamin D. Nephrocalcinosis, renal stones and im- uremic rats that were treated with two different doses
paired renal function are common [30]. Since it is often of R-568 for 4 days were compared to those receiving
vehicle. The degree of proliferation of the parathyroiddifficult to separate effects of the basic disorder from
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cells, as assessed by BrdU labelling, was reduced by 20 PTH was reduced by more than 60% after the first dose
in 6 of 7 patients. After 24 hr, the pretreatment PTHand 50% by the low and high doses of R-568, respec-
tively. There were no effects found in other proliferating level was still 50% lower than the initial basal value;
nonetheless, the PTH fell 50% or more after the secondtissues. Parathyroid cell volume was reduced only with
the high dose, although increased apoptosis was not dose in 6 of 7 patients. Blood Ca21 was not changed
significantly after the low dose but fell significantly afterfound [39]. The effect of R-568 on osteitis fibrosa was
evaluated in another study of uremic rats [40]. Two dif- the high dose (Table 2). Preliminary data from hemodial-
ysis patients with severe secondary hyperparathyroidismferent doses of the calcimimetic were given daily for 30
days; there was a dose-related reduction of PTH levels, (abstract; J Am Soc Nephrol 9:516A, 1998) revealed sig-
nificant reductions after 100 mg and even greater reduc-and there was marked improvement in the degree of
osteitis fibrosa. The reductions of cortical bone mineral tions after 200 mg of R-568. The PTH levels had not
returned to baseline after 24 hr, when the second dosedensity and of bone stiffness that developed with second-
ary hyperparathyroidism were largely reversed by treat- caused a similar percentage reduction of PTH. Serum
total Ca levels fell, with more marked reductions afterment with R-568.
Several reports have documented the effectiveness of the larger dose. Calcitonin levels did not change after
either dose.single doses or of two daily doses of R-568 to reduce
PTH levels in patients with primary and secondary hyper- In a preliminary report (abstract; J Am Soc Nephrol
10:619A, 1999), the administration of R-568 in doses ofparathyroidism [41, 42; abstract; J Am Soc Nephrol 9:516A,
1998]. The initial clinical experiences with the calcimi- 100 mg per day led to the sustained suppression of PTH
levels that persisted for 15 days, the duration of treat-metic agent, R-568, in patients are summarized in Table
2. In primary and secondary hyperparathyroidism, a sin- ment. Hypocalcemia led to interruption of the study in
3 patients as the blood Ca21 fell below 1.0 mm.gle initial oral dose of R-568 produced a maximum sup-
pression of PTH levels, that was dose-dependent, at one All these short-term trials indicate that the calcimi-
metic, R-568, effectively reduces plasma PTH levels into two hours after administration. The decrease in blood
Ca21 was significant only with the larger dose and oc- patients with mild primary hyperparathyroidism and
those with secondary hyperparathyroidism of varyingcured only after PTH levels fell. The percentage reduc-
tions of PTH from pretreatment values were remarkably severity. The duration of action following a dose was
substantially longer in the patients with end-stage renalsimilar following 100–200 mg doses of R-568, with the
average PTH reductions between 63% and 73% in two disease than in those with primary hyperparathyroidism
and normal renal function. In each study, there was areported studies [41, 42] and two preliminary reports (ab-
stract; J Am Soc Nephrol 9:516A, 1998; abstract; J Am reduction in blood Ca21 or total serum Ca that occured
after the PTH levels were reduced. The marked andSoc Nephrol 10:619A, 1999); this suppression was inde-
pendent of the pretreatment PTH, which averaged 77 consistent degree of reduction of PTH levels produced
by calcimimetic treatment of patients with widely differ-pg/ml in patients with primary hyperparathyroidism and
varied from 218 to 1287 pg/ml in the groups with second- ent PTH levels suggests that a decrease in CaR density
occuring in some parathyroid glands may be less impor-ary hyperparathyroidism.
In women with mild primary hyperparathyroidism, the tant than was initially believed.
The calcimimetic agent R-568 was given to a patientmaximal decrease in PTH occured by one hour after the
lowest doses of R-568, while it occurred at two hours with inoperable parathyroid carcinoma, who presented
with hypercalcemia (blood Ca21 1.96 mm), high PTHafter larger doses [41]. The duration of effect increased
with the dose; the PTH levels had returned to baseline levels (1128 pg/ml), and altered mental status; the hyper-
calcemia failed to respond to intravenous saline and furo-by four hours after doses of 80 mg or less but returned
to baseline only at 8 hr after the 160 mg dose. A small semide, several doses of intravenous pamidronate and
salmon calcitonin over 18 days [43]. The calcimimeticbut significant reduction of blood Ca21 occured only with
the largest dose, 160 mg. After this dose, urinary calcium, was initiated at 200 mg/day and subsequently increased
to 400 mg/day. The patient’s symptoms improved afterexpressed as the calcium/creatinine ratio, rose by four
hours but returned close to baseline by 8 hr. three days of R-568 treatment, and he was discharged
home after 28 days of treatment with a blood Ca21 ofTwo trials in dialysis patients with secondary hyper-
parathyroidism employed two separate doses of R-568, 1.53 mm and PTH level of 357 pg/ml. Treatment with
the calcimimetic was continued and the dose was titratedeach given on two successive days [42, abstract; J Am
Soc Nephrol 9:516A, 1998]. In seven patients with mild up to 600 mg/day; this treatment maintained the total
serum calcium between 2.75 and 3.0 mm despite the pro-hyperparathyroidism [42], doses of 40 or 80 mg caused
PTH levels to fall by more than 30% after the first dose gressive increase in PTH levels to 2000–3500 pg/ml; this
PTH increase probably occured due to progression ofin 5 of 7 patients and more than 60% after the second
dose in 6 of 7 patients. With doses of 120 and 200 mg, the parathyroid carcinoma. The patient remained active,
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